243 results on '"Londoño, María‐Carlota"'
Search Results
2. Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis
3. Recommendations and quality criteria to improve the early diagnosis of primary biliary cholangitis
4. Recomendaciones y criterios de calidad para mejorar el diagnóstico precoz de la colangitis biliar primaria
5. Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study
6. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
7. Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis
8. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients
9. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy
10. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report
11. Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study
12. Enhanced recovery for liver transplantation: recommendations from the 2022 International Liver Transplantation Society consensus conference
13. Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans
14. WED-155 A ratio of exchangeable copper below 15% accurately excludes Wilson disease and may be useful for the first-line ethiologic work-up within a liver unit
15. LBP-040 Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): interimresults for 2 years from the ASSURE study
16. FRI-211 The presence of autoimmune characteristics in metabolic associated steatosis liver disease patients increases the risk of liver disease progression. Study from the multicentric spanish register (HEPAMET)
17. THU-155 Incidence of fungal and other opportunistic infections in patients with autoimmune hepatitis: a spanish multicentre study
18. THU-102-YI Specific glycomic profiles can identify patients at risk of poor transplant-free survival in primary biliary cholangitis
19. THU-170-YI Paris II criteria are better than Poise to predict liver-related complications after second line therapy in patients with primary biliary cholangitis
20. FRI-321 Clinical and molecular features of immune-mediated and drug-induced liver injury
21. THU-154-YI Diabetes mellitus (DM) is associated with worse outcomes in patients with primary biliary cholangitis (PBC) regardless of the presence of liver steatosis: results from the ColHai registry
22. WED-153 Advances in the diagnosis of cholestatic liver diseases with the implementation of exome sequencing
23. THU-098 Appraising gain of an extended 2-year placebo-controlled trial in primary biliary cholangitis: challenges for evaluating clinical outcomes
24. THU-118 Prophylaxis for tuberculosis and pneumocystis jirovecii does not seem necessary in patients with autoimmune hepatitis treated with corticosteroid therapy: spanish multicentre study
25. Budesonide in the first line treatment of patients with autoimmune hepatitis
26. Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry.
27. Impact of donor extracellular vesicle release on recipient cell “cross-dressing” following clinical liver and kidney transplantation
28. Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study
29. On the impact of hepatitis C virus and heterologous immunity on alloimmune responses following liver transplantation
30. Ductular reaction and hepatocyte ballooning identify patients with fibrosing cholestatic hepatitits after liver transplantation
31. Anticancer drugs are the first cause of drug‐induced liver injury in a reference hospital
32. Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis
33. Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV–cirrhotic patients
34. Calidad de vida en los pacientes con hepatitis C. Importancia del tratamiento
35. Simplified follow-up of patients with mild chronic hepatitis C in areas with limited access to antiviral therapy
36. Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia
37. Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients
38. Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure
39. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition
40. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
41. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus–Associated Cryoglobulinemia Treated With Direct-Acting Antivirals
42. Anticancer drugs are the first cause of drug- induced liver injury in a reference hospital.
43. Conferring alloantigen specificity to regulatory T cells: A comparative analysis of cell preparations undergoing clinical development in transplantation
44. Detection of M2-Type Anti-Mitochondrial Autoantibodies against Specific Subunits in the Diagnosis of Primary Biliary Cholangitis in Patients with Discordant Results
45. Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents
46. Treatment of Hepatitis C Before Liver Transplantation
47. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
48. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy
49. Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney
50. Beneficial Effect of Ursodeoxycholic Acid in Patients with ACOX2 Deficiency-Associated Hypertransaminasemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.